Data layers Raw facts Calculated Model prediction AI interpretation

Cross-Market Price Comparison

Other Listed Market Shanghai (SSE) — 复星医药
Other Market Stock Code600196
H-Share Offer PriceTo be extracted
Other Market PriceLoading...
Reference Exchange RateLoading...
H-Share Offer Price Premium/Discount vs Other MarketLoading...

Company Overview

Stock NameFosun Pharma
Stock Code02196
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities本公司為中國領先的醫藥健康公司,業務戰略性覆蓋醫藥健康產業價值鏈多個重要環節,核心業務為藥品研發、生產、銷售及營銷,業務分部包括製藥、藥品分銷及零售、醫療服務以及診斷產品與醫療器械。
Listing Date2012-10-30
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國上海 普陀區 曹楊路510號9樓 郵編:200063
Business Address (Hong Kong)香港 皇后大道東1號 太古廣場三座 28 樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitefosunpharma.com
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingYes (A股)

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 11.80 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueRMB 1.0 / shares
Offer Period2012-10-17 to 2012-10-22
Global Offering Shares336,070,000 shares
HK Public Offer Shares (Initial)33,607,000 shares (10.0%)
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)302,463,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO2,240,462,364 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share14.6%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 3,965,626,000

Stock Connect Inclusion Analysis

HK Market Cap HK$ 9.19B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利约人民币1,166.2百万元
Period-End Cash Balance人民币2,894.6百万元
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 2009201020112012-06
Profit before tax 3,267,4771,201,9511,727,238987,229
Profit for the year 2,567,0811,000,3441,385,419857,769
Balance Sheet
Item 2009201020112012-06
Cash and cash equivalents 1,296,7613,343,5552,894,5731,743,582
Trade and bills receivables 680,3331,058,4071,147,7001,237,591
Inventories 597,993932,7741,123,9431,230,602
Total current assets 2,831,6335,879,9876,049,1065,284,467
Total assets 11,470,25916,776,05422,233,93122,265,269
Total current liabilities 2,498,3423,697,6934,991,7263,994,706
Total liabilities 4,575,1167,421,05610,919,99010,573,769
Total equity 6,895,1439,354,99811,313,94111,691,500
Equity attributable to owners 6,419,6358,366,1369,714,97610,083,827
Interest-bearing borrowings 2,869,2634,590,4496,093,8686,143,842
Cash Flow Statement
Item 2009201020112012-06
Net cash from operating activities 261,869203,363316,650230,908
Net cash from investing activities -371,043-262,394-1,706,175-736,884
Net cash from financing activities 374,2181,820,548852,632-462,470
Net increase in cash 265,0441,761,517-536,893-968,446
Depreciation of PP&E 126,503144,129172,299110,471
Amortisation of intangible assets 5,7024,28628,01625,791
Purchase of PP&E -348,068-339,167-796,833-619,843
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 10.84
First Day OpenHK$ 11.08
First Day Change-8.14%
First Day Volume54273500.0
First Day Turnover588861000.0
Use of Proceeds
1、約48%或1,806.9百萬港元將用于制藥、醫藥分銷及零售、醫藥健康、診斷產品及醫療器械領域的收購及合并; 2、約19%或715.2百萬港元將用于為現有的研發項目、擴充我們的研發團隊及收購新的研發項目融資; 3、約23%或865.8百萬港元將用于償還本集團的部分帶息負債的本金及利息; 4、約10%或376.4百萬港元將用于補充本集團的營運資金。

Underwriting Syndicate

Joint Sponsors (4)
UBS Securities Hong Kong Limited CE BIN466 中国国际金融香港证券有限公司 CE AEN894 J.P. Morgan Securities (Far East) Limited CE AAB026 Deutsche Bank AG, Hong Kong Branch CE AAK077
Overall Coordinators (4)
UBS Securities Hong Kong Limited CE BIN466 中国国际金融香港证券有限公司 CE AEN894 J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321 Deutsche Bank AG, Hong Kong Branch CE AAK077
Joint Bookrunners (4)
UBS Securities Hong Kong Limited CE BIN466 中国国际金融香港证券有限公司 CE AEN894 J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321 Deutsche Bank AG, Hong Kong Branch CE AAK077
Joint Lead Managers (4)
UBS Securities Hong Kong Limited CE BIN466 中国国际金融香港证券有限公司 CE AEN894 J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321 Deutsche Bank AG, Hong Kong Branch CE AAK077

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 The Prudential Insurance Company of America 387,624,100 HKD — 9.77% — 6 months 2013-04-30
2 国际金融公司 191,160,000 HKD — 4.82% — 6 months 2013-04-30

Directors & Management

PositionChinese nameEnglish Name
Chairman陳玉卿,關曉暉—
Company Secretary喬志城、盧綺霞—
No director data available.

Major Shareholders

Major Shareholders & Holdings復星高科技、復星國際、復星控股及復星國際控股各持有917,922,361股A股,佔48.20%;郭廣昌先生持有918,036,436股A股,佔48.21%;梁信軍先生持有201,968,016股A股,佔10.61%。
About this page

This page shows Fosun Pharma (02196) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect